Cargando…
PARP inhibitors in the management of breast cancer: current data and future prospects
Poly(ADP-ribose) polymerases (PARP) are enzymes involved in DNA-damage repair. Inhibition of PARPs is a promising strategy for targeting cancers with defective DNA-damage repair, including BRCA1 and BRCA2 mutation-associated breast and ovarian cancers. Several PARP inhibitors are currently in trials...
Autores principales: | Livraghi, Luca, Garber, Judy E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4535298/ https://www.ncbi.nlm.nih.gov/pubmed/26268938 http://dx.doi.org/10.1186/s12916-015-0425-1 |
Ejemplares similares
-
PARP inhibition in breast cancer: progress made and future hopes
por: Tung, Nadine, et al.
Publicado: (2022) -
Current status and future prospects of PARP inhibitor clinical trials in ovarian cancer
por: Jiang, Xuan, et al.
Publicado: (2019) -
Moving beyond PARP Inhibition: Current State and Future Perspectives in Breast Cancer
por: Palleschi, Michela, et al.
Publicado: (2021) -
Current Evidence and Future Perspectives about the Role of PARP Inhibitors in the Treatment of Thoracic Cancers
por: Parisi, Alessandro, et al.
Publicado: (2023) -
PARP Inhibitors in Breast and Ovarian Cancer
por: Wang, Samuel S. Y., et al.
Publicado: (2023)